Expanded Access in 2025: What the FDA’s New Q&A Guidance Document Means for Sponsors
Background The US FDA has a long history of facilitating expanded access (EA) to promising new investigational drugs for patients suffering from serious or life-threatening conditions who have no viable alternative treatment options available to them. In [...]








